Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant peginterferon alfa-2b versus observation in ulcerated primary cutaneous melanoma
NL-OMON43578Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cutaneous melanoma (CM) comparing Peginterferon alfa-2b with Observation (2 arms). Primary endpoint: Relapse-free survival. Started Aug 2015; status: active, not recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON43578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43578.